From GlobeNewswire: 2025-02-18 10:00:00

The Personalized Medicine Biomarkers Market was valued at USD 17.26 billion in 2023, projected to reach USD 58.39 billion by 2032, with a CAGR of 14.54%. Increasing demand for targeted therapies, early disease detection, and novel biomarkers are driving market growth.

Precision medicine customization is fueled by biomarkers for disease risk, treatment response, and progression. Next-gen technologies like NGS and proteomics improve diagnostic accuracy. Government funding boosts research, with initiatives like the All of Us Program and Horizon Europe investing in genomic research and biomarker development.

In 2023, the early detection/screening segment dominated the market at 35% revenue share. Biomarkers aid in early treatment, like PSA for prostate cancer screening and CA-125 for ovarian cancer. Treatment selection segment growth is anticipated, with biomarkers guiding therapy choices, especially in oncology.

The oncology segment led with 41% share in 2023, driven by cancer prevalence and precision oncology adoption. Biomarkers like PD-L1 and KRAS guide cancer diagnosis and treatment. Diabetes segment shows rapid growth, driven by global diabetes burden and demand for personalized treatments using biomarkers like HbA1c and C-peptide.

North America held 43% share of the market in 2023, with advanced healthcare infrastructure and high precision medicine adoption driving growth. Initiatives like PMI and the Cancer Moonshot Program in the US contribute significantly to the market. Major global market players such as Roche Diagnostics, Thermo Fisher Scientific, Illumina dominate the Asia-Pacific market, positioning it for rapid growth. Government-funded programs in China, India, and Japan focus on precision medicine, driving personalized medicine initiatives. Recent developments include Roche’s liquid biopsy for NSCLC and Illumina’s FDA-approved sequencing system for biomarker discovery.

In 2023, Roche Diagnostics introduced a liquid biopsy for NSCLC, while Illumina received FDA approval for a sequencing system in January 2024. The Asia-Pacific region is poised for growth with key players dominating the market and government-funded programs driving personalized medicine initiatives in countries like China, India, and Japan.

SNS Insider, a leading market research agency, offers a detailed report on the Personalized Medicine Biomarkers Market from 2024-2032. The report includes market dynamics, statistical insights, company profiles, and regional analysis. With a focus on providing accurate market data and consumer insights, SNS Insider aims to empower clients to make informed decisions in a changing market landscape.



Read more at GlobeNewswire: Personalized Medicine Biomarkers Market Size to Hit USD